DTM™ SCS endurance therapy Spinal cord stimulation

DTM™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.

Download clinical results

DTM™ SCS endurance
therapy overview

Inspired by science

DTM™ SCS therapy options are inspired by decades of basic science research and preclinical understanding. In a preclinical study, the DTM™ programming (DTMP) derivatives modulated neuro-inflammatory processes more than low-rate SCS.*2

Clinical results show meaningful pain relief

Study objectives

DTM™ SCS endurance therapy study is a prospective, multicenter, single-arm study designed to evaluate the long-term efficacy and energy use of DTM™ SCS endurance therapy.1

Primary objective: To evaluate the effectiveness of DTM™ SCS endurance therapy in reducing overall pain intensity at 3-months follow up.

Secondary objectives with follow up to 12-months:

  • Characterize changes in pain intensity for overall, back, and leg pain
  • Characterize programming parameters associated with energy use
  • Characterize changes in functional disability as measured by Oswestry disability index (ODI)
  • Characterize subject satisfaction
  • Characterize therapy safety data

Study outcomes

pain relief


reduction in VAS for overall pain
from baseline to 3 months1

Changes in pain

Meaningful quality of
life improvements


of patients had minimal to moderate disability
at 3 months compared to only 16% at baseline1

Quality of life

Therapy satisfaction


of patients are very or somewhat
satisfied with therapy1

Long lasting


years of recharge-free longevity
estimated using actual 3-month
programming data3

Save time

5 minutes

estimated daily rapid recharge
or recharge less frequently
(1 hour every 12 days)3

pain relief

DTM™ SCS offers proven pain relief backed by data on Intellis™ SCS. Learn about the therapy.


Vanta™ SCS neurostimulator

High performance and recharge free. Experience DTM™ SCS endurance therapy on Vanta™.

Learn more

Intellis™ SCS neurostimulator 

Rapid recharge available with DTM™ SCS or DTM™ SCS endurance therapy. 

Discover Intellis™ SCS

*Note: Data obtained from animal studies should not be extrapolated to clinical/human results.


Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients: Primary endpoint and 3-month outcomes. Poster presented at: North american neuromodulation society (NANS) annual meeting. Jan. 13-15, 2022.


Cedeno D, Vallejo R, Platt D, et al. Differential target multiplexed SCS using reduced energy parameters in an animal model of neuropathic pain. Poster presented at: American Society of Pain and Neuroscience (ASPN) annual meeting. July 22-25, 2021.


Provenzano, Amirdelfan, Grewal, et al. Modeling energy demands of a reduced-energy derivative of differential target multiplexed™ stimulation on rechargeable and recharge-free systems. Poster presented at North American Neuromodulation Society (NANS). January 13-15, 2022.